Ten selected publications.

1. A Non-Isotopic Assay for Histone Deacetylase Activity. K. Hoffmann, G. Brosch,
P. Loidl, M. Jung; Nucleic Acids Res. 27 (1999), 2057-2058.
2. Identification of selective inhibitors of NAD+-dependent deacetylases using phenotypic screening in yeast. M. Hirao, J. Posakony, M. Nelson, H. Hruby, M. Jung, J. A. Simon, A. Bedalov; J. Biol. Chem. 278 (2003), 52773-52783.

(…)

Ten selected publications.

1. A Non-Isotopic Assay for Histone Deacetylase Activity. K. Hoffmann, G. Brosch,
P. Loidl, M. Jung; Nucleic Acids Res. 27 (1999), 2057-2058.
2. Identification of selective inhibitors of NAD+-dependent deacetylases using phenotypic screening in yeast. M. Hirao, J. Posakony, M. Nelson, H. Hruby, M. Jung, J. A. Simon, A. Bedalov; J. Biol. Chem. 278 (2003), 52773-52783.
3. Induction of human gamma globin gene expression by histone deacetylase inhibitors. H. Cao, G. Stamatoyannopoulos, M. Jung; Blood 103 (2004), 701-709.
4. Subtype selective substrates for histone deacetylases. B. Heltweg, F. Dequiedt,
B. L. Marshall, C. Brauch, M. Yoshida, N. Nishino, E. Verdin, M. Jung; J. Med. Chem. 47 (2004), 5235-5243.
5. SIRT1 regulates HIV transcription via Tat deacetylation. S. Pagans, A. Pedal, B. J. North, K. Kaehlcke, B. L. Marshall, A. Dorr, C. Hetzer-Egger, P. Henklein, R. Frye, M. W. McBurney, H. Hruby, M. Jung, E. Verdin, M. Ott; PloS Biology; 3 (2005), e41.
6. Adenosine mimics as inhibitors of NAD+-dependent histone deacetylases – from kinase to sirtuin inhibitors. J. Trapp, A. Jochum, R. Meier, L. Saunders, B. Marshall,
E. Verdin, P. Goekjian, C. Kunick, W. Sippl, M. Jung; J. Med. Chem. 49 (2006), 7307-7316.
7. Target-based approach to inhibitors of histone arginine methyltransferases.
A. Spannhoff, R. Heinke, I. Bauer, P. Trojer, E. Metzger, R. Gust, R. Schüle, G. Brosch, W. Sippl, M. Jung, J. Med. Chem. 50 (2007), 2319-2325.
8. Characterization of novel inhibitors of histone acetyltransferases. E. D. Eliseeva,
V. Valkov, M. Jung, M. Jung; Mol. Cancer Ther. 6 (2007), 2391-2398.
9. Structure activity studies on splitomicin derivatives as sirtuin inhibitors and computational prediction of binding mode. R. C. Neugebauer, U. Uchiechowska,
R. Meier, H. Hruby, V. Valkov, E. Verdin, W. Sippl, M. Jung; J. Med. Chem. 51 (2008) 1203-1213.
10. Therapeutic destabilization of ERBB2 transcripts by targeting 3’ UTR mRNA associated HuR and histone deacetylase-6 (HDAC6). G. K. Scott, C. Marx, C. E. Berger, L. R. Saunders, E. Verdin, S. Schäfer, M. Jung, C. C. Benz; Mol. Cancer Res. 6 (2008) 1250-1258.

Show all publications Only show few publications